Novo Nordisk Wegovy Strategy Boom With HD Dose Push
Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief The Wegovy HD…
Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide
Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to Eli Lilly? Maik Kemper Editor in Chief Conclusion…
Novo Nordisk FDA warning: Safety shock and WHO funding pivot
Can the Novo Nordisk FDA warning derail the GLP-1 boom just as a new WHO partnership reshapes the company’s global image? How serious is the Novo Nordisk FDA…
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the Novo Nordisk Hims…